Hisamitsu Pharmaceutical Co., Inc. (TYO:4530)
Japan · Delayed Price · Currency is JPY | Market Cap | 425.23B +53.0% |
| Revenue (ttm) | 163.02B +4.5% |
| Net Income | 19.16B -11.9% |
| EPS | 268.22 -9.1% |
| Shares Out | 70.40M |
| PE Ratio | 22.52 |
| Forward PE | 35.05 |
| Dividend | 45.00 (0.75%) |
| Ex-Dividend Date | n/a |
| Volume | 679,000 |
| Open | 6,040.00 |
| Previous Close | 6,040.00 |
| Day's Range | 6,040.00 - 6,050.00 |
| 52-Week Range | 3,861.00 - 6,695.00 |
| Beta | 0.29 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 9, 2026 |
About TYO:4530
Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company offers OTC products, such as external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete's foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders. It also exports its products to Asi... [Read more]
Full Company ProfileFinancial Performance
In fiscal year 2026, TYO:4530's revenue was 163.02 billion, an increase of 4.50% compared to the previous year's 156.01 billion. Earnings were 19.16 billion, a decrease of -11.94%.
Financial StatementsNews
Japan's Hisamitsu Pharmaceutical plans $2.55 billion MBO
Japan's Hisamitsu Pharmaceutical is planning to take the company private in a management buyout for nearly 400 billion yen ($2.55 billion), it said in a filing late on Tuesday.